news
AstraZeneca to acquire Takeda’s respiratory business
17 December 2015 | By Victoria White
AstraZeneca is to acquire the core respiratory business of Takeda for $575 million, adding Daxas to its portfolio...
List view / Grid view
Takeda Pharmaceutical Company Limited
news
Takeda’s Ninlaro capsules now available in the US
14 December 2015 | By Victoria White
Takeda’s Ninlaro (ixazomib) capsules, the first and only oral proteasome inhibitor, are now available in the US for patients with multiple myeloma...
news
Takeda announces new data for Adcetris in Hodgkin lymphoma
7 December 2015 | By Victoria White
Takeda presented long-term data from a Phase II and Phase III trial of Adcetris (brentuximab vedotin) at the 57th American Society of Hematology (ASH) annual meeting...
news
FDA approves Ninlaro for multiple myeloma
23 November 2015 | By Victoria White
Ninlaro (ixazomib) is the first and only oral proteasome inhibitor, indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma...
news
Phase 3 trial of Adcetris in Hodgkin lymphoma completes target enrolment
27 October 2015 | By Victoria White
Data from a Phase 1 trial evaluating Adcetris plus AVD demonstrated that 24 of 25 patients (96 percent) achieved a complete remission...
news
FDA grants Priority Review to ixazomib for multiple myeloma
10 September 2015 | By Victoria White
Ixazomib is the first investigational oral proteasome inhibitor for the treatment of patients with relapsed and/or refractory multiple myeloma...
news
NICE recommends vedolizumab for Crohn’s Disease
26 August 2015 | By Victoria White
NICE has recommended Vedolizumab, the first gut-selective treatment for Crohn's Disease, for use on the NHS, recognising the innovation of the treatment...
news
EMA accepts MAA for multiple myeloma drug ixazomib
21 August 2015 | By Victoria White
Takeda has announced that the EMA has accepted is Marketing Authorisation Application for ixazomib for the treatment of patients with multiple myeloma...
news
EMA grants accelerated assessment to ixazomib
27 July 2015 | By Victoria White
The CHMP of the EMA has granted an accelerated assessment to ixazomib for the treatment of patients with relapsed and/or refractory multiple myeloma...
news
Takeda submits NDA in the US for ixazomib for the treatment of multiple myeloma
15 July 2015 | By Victoria White
Takeda has submitted an NDA to the US FDA for ixazomib for the treatment of patients with relapsed and/or refractory multiple myeloma...
news
New analysis from Phase 3 trial of Adcetris in Hodgkin’s lymphoma patients presented at ICML 2015
22 June 2015 | By Victoria White
Results from a new sub-analysis of the Phase 3 Aethera clinical trial of Adcetris were presented at the 13th International Conference on Malignant Lymphoma...
news
Takeda discontinues alisertib Phase 3 trial in relapsed or refractory peripheral T-cell lymphoma
15 May 2015 | By Victoria White
Takeda has decided to discontinue the Phase 3 trial of alisertib (MLN8237) for patients with relapsed or refractory peripheral T-cell lymphoma (PTCL)...
news
First patient enrolled in Phase 3 study of ixazomib as maintenance therapy for newly diagnosed multiple myeloma
12 May 2015 | By Victoria White
Takeda has announced that the first patient has been enrolled in the Phase 3 TOURMALINE-MM4 study of investigational oral ixazomib...
news
New post-hoc analyses extend understanding of the efficacy and safety of lurasidone in the treatment of schizophrenia
31 March 2015 | By Victoria White
Takeda and Sunovion today announced the results from 3 post-hoc analyses evaluating the efficacy and safety of lurasidone in patients with schizophrenia...
news
Takeda announces appointment of Marc Princen as President of the EUCAN Business Unit
4 November 2014 | By Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited have announced that Marc Princen joined Takeda Pharmaceuticals International GmbH as Corporate Officer and President of the EUCAN (Europe and Canada) Business Unit...
